Changes in Hong Kong stocks | Conoa-B (02162) rose more than 8% in the intraday period. The company has a strong competitive advantage in many innovative drug fields such as self-defense and oncology

The Zhitong Finance App learned that Conoa-B (02162) rose more than 8%. As of press release, it had risen 6.26% to HK$77.8, with a turnover of HK$144 million.

According to the news, at the beginning of this month, Conocar announced that it had reached a licensing agreement with the multinational pharmaceutical company Aeira for the listing registration and commercialization of septicimab injections in 18 countries and regions, including Southeast Asia and Central Asia. China Post Securities pointed out that as an innovative domestic drug, Connoya has a strong competitive advantage in various innovative drug fields such as self-defense and oncology. The company's core pipeline is already on the market, and the volume of medical insurance increased rapidly in the first year. The superposition of basic drugs is expected to improve and open up market space. Furthermore, the innovative pipeline has completed a number of overseas BDs, which is expected to open up the global market. At the same time, the cooperative AZ pipeline has obtained positive results for phase 3, improving the certainty of global commercialization.

It is worth mentioning that Summit Therapeutics, an overseas partner of Kangfang Biotech, has reached a strategic cooperation with AstraZeneca. AstraZeneca will invest 2 billion US dollars in strategic equity investment in Summit, and plans to take the lead in promoting the clinical research of Sonesitatug Vedotin (Sone-Ve, CLDN18.2 ADC) of Evarosi and AstraZeneca for various gastrointestinal tumors. According to reports, Sone-VE, formerly known as CMG901, is a Claudin18.2 ADC developed by KYM (both parties hold 70% and 30% shares, respectively), a joint venture between Conoah and Lepu Biotech. In February 2023, AstraZeneca took over its global equity with a $63 million down payment and a milestone payment of over $1.1 billion.